Study results provide much-anticipated details to Summit’s claim earlier this year that its drug “decisively beat” Merck’s dominant immunotherapy.

J&J did not provide Auris Health with resources to achieve regulatory milestones after acquiring the robotics company in 2019, the judge found.

OrsoBio is advancing several weight loss medicines. Elsewhere, Boehringer Ingelheim pushed forward with a geographic atrophy drug and Vaxcyte raised $1.3 billion.

New trial results could offer support for an expansion of Nucala’s label after U.S. regulators rejected GSK’s submission in 2018.

With this funding round, Clouds of Care appoints two experienced life science professionals to the board of directors; Michel Vounatsos, former CEO of biotech company Biogen, is welcomed as chairman, ...

The CEO of Lykos Therapeutics will step down after the company’s efforts to win a milestone approval for MDMA as a therapy aid were rejected by the Food and Drug Administration last month. Amy Emerson ...

New data show Lilly’s longer-lasting insulin matched daily shots in controlling blood sugar, adding to positive findings the company disclosed in May.

Analysts and investors have dialed back their expectations for tolebrutinib since Sanofi bought its developer, Principia Biopharma, four years ago. The drug is part of a newer generation of would-be ...